Viatris Inc. (VTRS)

The investment case for Viatris is currently bifurcated between a distressed dividend yield and a deteriorating business trajectory. While the 2.94% yield appears attractive on the surface, it masks a company with negative trailing earnings (-$0.30 EPS) and a forward P/E that relies entirely on a turnaround story rather than current profitability. The balance sheet is fragile, carrying nearly $14.6 billion in debt against only $2.4 billion in cash, resulting in a debt-to-equity ratio nearing 100%. This leverage creates a constant overhang that suppresses the stock's ability to rally despite modest revenue growth. The price history confirms this structural weakness. Over the last nine years, the stock has lost nearly 80% of its value, with seven out of nine years showing negative returns. Although the most recent annual drop was isolated, the cumulative trend is unmistakably bearish, reflecting a market that has repeatedly punished the company's performance. The recent price action shows a slight uptick, trading above its 200-day average, but this appears to be a technical rebound rather than a fundamental reversal, especially given the heavy put positioning by options traders who are betting on continued weakness. For the long term, the company faces the challenge of navigating generic drug patent cliffs while managing significant debt obligations. Until the balance sheet is strengthened and consistent profitability is restored, the risk of a 'value trap'—where the low price reflects permanent damage rather than a temporary dislocation—is high. The dividend, while stable in amount, is paid on a shrinking equity base and negative earnings, making its sustainability questionable in a prolonged downturn. Investors should view this as a high-risk turnaround play rather than a core holding.